{"id":115160,"date":"2025-12-23T17:59:08","date_gmt":"2025-12-23T17:59:08","guid":{"rendered":"https:\/\/www.europesays.com\/se\/115160\/"},"modified":"2025-12-23T17:59:08","modified_gmt":"2025-12-23T17:59:08","slug":"danskt-lakemedelsbolag-rusade-pa-borsen-efter-godkannande-av-viktminskningsmedel-i-usa-ekonomi","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/115160\/","title":{"rendered":"Danskt l\u00e4kemedelsbolag rusade p\u00e5 b\u00f6rsen efter godk\u00e4nnande av viktminsknings\u00admedel i USA | Ekonomi"},"content":{"rendered":"

Wegovy i pillerform godk\u00e4ndes av myndigheterna f\u00f6r f\u00f6rs\u00e4ljning USA.<\/p>\n

\"En<\/p>\n

\u00d6ppna bildvisare<\/p>\n

Wegovypiller f\u00e5r nu s\u00e4ljas i USA. Bild: Ida Marie Odgaard \/ EPALyssna (du h\u00f6r en artificiell r\u00f6st) 1:05<\/p>\n

Den danska l\u00e4kemedelsj\u00e4tten Novo Nordisks viktminskningspiller Wegovy godk\u00e4ndes f\u00f6r f\u00f6rs\u00e4ljning i USA i m\u00e5ndags kv\u00e4ll.<\/p>\n

Efter det steg bolagets aktiekurs med \u00f6ver nio procent under tisdagen.<\/p>\n

Novo Nordisk har haft ett h\u00e5rt \u00e5r med kraftig kursnedg\u00e5ng. Att pillren nu kommer att f\u00e5 s\u00e4ljas i USA \u00e4r en stor seger f\u00f6r bolaget, som i h\u00f6stas meddelade om personalnedsk\u00e4rningar.<\/a><\/p>\n

Tidigare har Wegovy bara f\u00e5tt s\u00e4ljas som injektioner i USA, men nu kan det allts\u00e5 s\u00e4ljas i pillerform. L\u00e4kemedlet ber\u00e4knas kunna n\u00e5 miljontals potentiella patienter.<\/p>\n

Novo Nordisk st\u00e5r ocks\u00e5 bakom l\u00e4kemedlet Ozempic, som blivit popul\u00e4rt f\u00f6r viktminskning \u00e4ven om det prim\u00e4rt varit avsett som ett l\u00e4kemedel f\u00f6r vuxna med typ 2-diabetes.<\/p>\n

Wegovy \u00e4r d\u00e4remot utvecklat specifikt som bantningsmedel.<\/p>\n

K\u00e4lla: Reuters<\/p>\n","protected":false},"excerpt":{"rendered":"Wegovy i pillerform godk\u00e4ndes av myndigheterna f\u00f6r f\u00f6rs\u00e4ljning USA. \u00d6ppna bildvisare Wegovypiller f\u00e5r nu s\u00e4ljas i USA. Bild:…\n","protected":false},"author":2,"featured_media":115161,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[12479,72,1205,70,71,5106,2958,3904,1206,444,34,31,33,32,30,12478,74],"class_list":{"0":"post-115160","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-borser","9":"tag-business","10":"tag-danmark","11":"tag-economy","12":"tag-ekonomi","13":"tag-foretag","14":"tag-lakemedelsindustri","15":"tag-mediciner","16":"tag-novo-nordisk","17":"tag-ozempic","18":"tag-se","19":"tag-svenska","20":"tag-sverige","21":"tag-sweden","22":"tag-swedish","23":"tag-typ-2-diabetes","24":"tag-usa"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115770187448208058","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/115160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=115160"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/115160\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/115161"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=115160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=115160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=115160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}